The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities
| Autor: | Helga, Hansdóttir, Leifur, Franzson, Karen, Prestwood, Gunnar, Sigurdsson |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Selective Estrogen Receptor Modulators
Time Factors Acid Phosphatase Osteocalcin Bone and Bones Collagen Type I Phosphates Fractures Bone Sex Factors Bone Density Risk Factors Humans Vitamin D Osteoporosis Postmenopausal Aged Aged 80 and over Age Factors Alkaline Phosphatase Long-Term Care Nursing Homes Parathyroid Hormone Data Interpretation Statistical Raloxifene Hydrochloride Calcium Female Bone Remodeling Biomarkers |
| Zdroj: | Journal of the American Geriatrics Society. 52(5) |
| ISSN: | 0002-8614 |
| Popis: | To examine the effect of raloxifene on bone turnover in elderly women.Clinical intervention.Long-term care facilities.Nineteen women completed the study, mean age 85 (range 76-99).Raloxifene 60 mg was given daily for 12 weeks.Markers of bone turnover were plasma C-telopeptides of type I collagen (CTx), urine cross-linked N-telopeptides of type I collagen (NTx) and serum tartrate-resistant acid phosphatase (TRAP 5b), plasma osteocalcin, and serum bone alkaline phosphatase. Other markers were serum 25-OH vitamin D, parathyroid hormone, ionized calcium, and phosphate. Markers were measured at baseline, after calcium and vitamin D had been taken for 6 weeks, after raloxifene had been taken for 12 weeks, and 6 weeks after raloxifene had been stopped. Paired sample t test was used to examine changes in markers at each time point.Plasma CTx decreased on average by 31%, urinary NTx by 35%, plasma osteocalcin by 25%, serum bone alkaline phosphatase by 15% (P.01), and serum TRAP 5b by 10% (P.05) on treatment.Raloxifene reduces bone turnover in elderly women living in long-term care facilities. The effect of raloxifene on bone turnover is comparable with that seen in younger postmenopausal women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text